Teva Pharmaceutical Industries has sold its women’s health portfolio in three separate agreements with total proceeds of US$2.48 B in order to pay off some of its acquired debt. The company has been struggling financially due to a combination of expensive acquisitions, pricing pressures in the generics market, and delayed drug launches.